Navigation Links
Neuftec Issues Patent Infringement Proceedings in the UK Against Oxonica
Date:6/12/2008

ROSEAU, Commonwealth of Dominica, June 12 /PRNewswire/ -- Neuftec Limited, the proprietor of the original nano-particulate cerium Oxide fuel catalyst technology, today commenced patent infringement litigation in the UK against Oxonica Energy Limited, a wholly owned subsidiary of Oxonica PLC . The proceedings, issued in the High Court of Justice, allege infringement of Neuftec's European patent.

The proceedings seek an injunction against Oxonica as well as damages in relation to product already sold and delivery up or destruction of all articles that would infringe Neuftec's European patent.

Oxonica and its legal advisors have previously made statements on at least two occasions that they have no intention of dealing with products that infringe any of Neuftec's issued patents. However, despite these statements it is with regret that this is the second time, to the best of Neuftec's knowledge, that Oxonica has infringed its granted patents.

The first infringement came in May 2007 when it came to Neuftec's knowledge that Oxonica infringed the claims of Neuftec's Australian patent by collecting a shipment of Envirox without the knowledge, consent or authorization of Neuftec. This stock is estimated by Neuftec to have a resale value of approximately US$1.8 million and cannot be used or sold without Neuftec's permission. It has been stored in a warehouse in Australia since March 2007.

The latest alleged infringement occurred when Oxonica shipped Envirox formulations to Italy for use in Italian Government laboratory emission testing.

Neuftec is continuing it's investigations with customers, distributors & agents of Oxonica to determine the extent of the alleged infringement

Neuftec is represented in these proceedings by Watson, Farley & Williams LLP & Mr. Mark Platts-Mills QC of 8 New Square, London.

About Neuftec

Neuftec is a research & development company that owns patents in the fuel catalyst technology sector used in the production of the first version of EnviroxTM (2001-2007) that was manufactured by Advanced Nanotechnology ("ANO") of Australia under a manufacturing licence granted by Oxonica with authorization from Neuftec.

On 29 February 2008, IP Australia issued a re-examination report in respect of Neuftec's Australian patent. The patent had been issued in 2006 with 10 claims. In the re-examination report, IP Australia confirmed the patentability of the 10 claims as originally granted in 2006 in re-examination proceedings initiated by Oxonica.


'/>"/>
SOURCE Neuftec Limited
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmos Issues Letter to Shareholders
2. MichBio Issues 2007/8 Michigan Life Sciences Directory and Resources Guide
3. HHS Issues First Department-Wide Report on Personalized Health Care
4. CalbaTech Issues Update; Beginning Training for Adult Stem Cell Collections in Atlanta
5. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
6. CCPM Issues Statement on FDAs GIVE Initiative
7. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
8. FDA Issues Approvable Letter for LUVOX(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD)
9. Baxter Issues Urgent Nationwide Voluntary Recall of Heparin 1,000 Units/mL 10 and 30mL Multi-Dose Vials
10. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
11. Solstice Neurosciences, Inc. Issues Corporate Response to FDA Early Communication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , ... May 25, 2016 , ... Scientists at the ... options being tried for mesothelioma may be hampering the research that could lead to ... Click here to read it now. , The team evaluated 98 ...
(Date:5/25/2016)... , ... May 25, 2016 , ... ... Food and Drug Administration (FDA) has granted the company’s orphan drug designation request ... second orphan drug designation granted by the FDA. , Spinocerebellar ataxia is ...
(Date:5/24/2016)... ... ... Last week, Callan Capital, an integrated wealth management firm specializing in asset ... Diego Life Science event at the Estancia La Jolla Resort and Spa. , Over ... Dr. Rich Heyman, former CEO of Aragon and Seragon, and Faheem Hasnain, former CEO ...
(Date:5/23/2016)... ... May 23, 2016 , ... PrecisionAg® ... Farming in 2017 and Beyond. The paper outlines the key trends that are ... industry. , “We’ve witnessed a lot of highs and lows as the precision ...
Breaking Biology Technology:
(Date:3/31/2016)... Florida , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange ... potential users of its soon to be launched online ... ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential ... use of DNA technology to an industry that is ...
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
(Date:3/22/2016)... March 22, 2016 ... Sensors Market for Consumer Industry by Type (Image, ... Application (Communication & IT, Entertainment, Home Appliances, ... Forecast to 2022", published by MarketsandMarkets, the ... to reach USD 26.76 Billion by 2022, ...
Breaking Biology News(10 mins):